Russell Investments Group Ltd. Has $5.73 Million Position in Lantheus Holdings Inc (LNTH)
Russell Investments Group Ltd. increased its position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 14.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 321,681 shares of the medical equipment provider’s stock after buying an additional 41,028 shares during the period. Russell Investments Group Ltd. owned about 0.86% of Lantheus worth $5,726,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new stake in Lantheus during the 2nd quarter worth $102,000. Municipal Employees Retirement System of Michigan purchased a new stake in Lantheus during the 2nd quarter worth $107,000. Quantbot Technologies LP purchased a new stake in Lantheus during the 2nd quarter worth $117,000. Sei Investments Co. increased its stake in Lantheus by 189.6% during the 3rd quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 5,126 shares during the period. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Lantheus during the 2nd quarter worth $141,000. 91.95% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Lantheus Holdings Inc (NASDAQ:LNTH) opened at $20.85 on Monday. The firm has a market cap of $782.00, a PE ratio of 18.62, a PEG ratio of 1.65 and a beta of 0.94. Lantheus Holdings Inc has a 1 year low of $7.95 and a 1 year high of $24.10. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46.
In related news, CFO John W. Crowley sold 6,755 shares of the business’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Derace L. Schaffer sold 15,000 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $17.50, for a total transaction of $262,500.00. Following the sale, the director now directly owns 48,730 shares of the company’s stock, valued at approximately $852,775. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,986 shares of company stock valued at $887,988. Insiders own 2.30% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 target price for the company in a research report on Tuesday, November 7th. Jefferies Group boosted their target price on shares of Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Credit Suisse Group boosted their target price on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 5th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.50.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Stock Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related stocks with our FREE daily email newsletter.